MMMonisha Madhumita

Monisha Madhumita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Monisha Madhumita has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    What people with psoriasis talk about online: Insights from a digital ethnography of lived experience

    by Dominique du Crest, Monisha Madhumita, Anjali Ancy, Jean François Penciolelli, Anjali Mahto, Sergio Vano-Galvan, Daniel Sugai, Dima Haidar, Raquel Vaz, Josef De Guzman, et al.

  • Open Access

    Artificial Intelligence in Indian Dermatology: An IADVL Academy Position Statement and Policy Framework for Safe, Equitable, and Effective Adoption

    by Siddharth Bhatt, Shital Poojary, Bushra I. Khan, Monisha Madhumita, Somesh Gupta, Senkadhir Vendhan

    Artificial intelligence (AI) systems, particularly deep learning models, are increasingly used in dermatology for image analysis, triage, remote monitoring, and decision support. For real-world adoption in the Indian dermatology ecosystem, robust validation, transparency, and governance are essential to protect patient safety and equity. This position statement synthesizes guidance from international dermatology societies and major regulatory approaches, and proposes India-adapted recommendations across clinical use, dataset curation, validation standards, ethics, privacy, liability, and policy. We performed a narrative synthesis of position statements from the American Academy of Dermatology (AAD), European Academy of Dermatology and Venereology (EADV), British Association of Dermatologists (BAD), and Australasian College of Dermatologists (ACD); regulatory frameworks, including the European Union Medical Device Regulation (EU MDR), the United States Food and Drug Administration (US FDA) Software as a Medical Device (SaMD) approach, National Institute for Health and Care Excellence (NICE) evidence standards, and Australia’s Therapeutic Goods Administration (TGA). Indian frameworks, including the Central Drugs Standard Control Organisation (CDSCO) Medical Device Rules, Bureau of Indian Standards/International Organization for Standardization (BIS/ISO) standards, the Digital Personal Data Protection (DPDP) Act, and Indian Council of Medical Research (ICMR) artificial intelligence ethics guidance were included. Seven domains were analyzed: governance, evidence generation, data bias, clinical safety, privacy, liability, and education. Principles emphasize clinician-in-the-loop use, prospective multicentric validation in representative Indian settings, skin-of-color inclusivity, transparent labeling and explainability, post-market surveillance, and clearer accountability. While clinical utility and health-economic evidence remain limited, validated and inclusive AI tools can responsibly expand access to quality dermatologic care in India, particularly in underserved areas.

  • The Cape Town Action Plan for Neglected Tropical Skin Diseases: From Workshop Consensus to Health‐System Action

    by Ramesha M. Bhat, Mariel Isa, Ketty Peris, Monisha Madhumita, Swathi Nagabushan, Emma van Rooijen, Henry W. Lim, Martin Röcken, María Ivonne Arellano Mendoza, Ncoza N. Dlova, et al.

    Skin‐related neglected tropical diseases (skin NTDs) remain visible markers of health‐system inequity. The World Health Organization (WHO) road map for neglected tropical diseases 2021–2030, its 2022 strategic framework for skin NTDs, and the WHO Global Report on Neglected Tropical Diseases 2025 already establish integration, primary‐care mainstreaming, and improved access to diagnostics and medicines as global priorities. Drawing on Workshop 1 of the 4th International League of Dermatological Societies (ILDS) World Skin Summit, this viewpoint positions the Cape Town Action Plan not as a competing policy framework, but as an implementation compact for translating existing commitments into locally owned service readiness, accountable delivery, and measurable follow‐through.

  • Digital ethnography in dermatology: studying patient experience where it now unfolds

    by Monisha Madhumita, Anjali Ancy, Dominique Ducrest

    The article describes digital ethnography as a useful anthropological technique to aid understanding of the lived experiences of patients with dermatological conditions, based on how they live their lives and skin conditions online. We describe the method, its usefulness and specific ethical limitations as relevant to dermatologists.

  • The rise of the skin bleaching crisis: global perspectives

    by Ncoza Cordelia Dlova, Olufolakemi Motunsope Cole-Adeife, Nkechi Anne Enechukwu, Monisha Madhumita, Jalil Alan Henry Mitchell

  • Open Access

    The Harmful Trifecta of Skincare in African and Asian Populations: Triple Action Creams, Skin‐Lightening Creams, and Antiseptic Soaps

    by Olufolakemi Cole‐Adeife, Monisha Madhumita, Doreen Mapunda, Daudi Mavura, Fatimata Ly

  • Open Access

    Startups Driving Artificial Intelligence Into Clinical Dermatology

    by Dominique Du Crest, Benjamin Miguel Monteagudo, Stanislas Vandier, Mullarkey Dan, Svedenhag Per, Jon Friis, Monisha Madhumita, Lilit Garibyan, Tu‐Anh Duong, Merete Haedersdal, et al.

    Artificial intelligence (AI) is rapidly transitioning from innovation to routine clinical application in dermatology. This review examines how AI‐enabled technologies are being developed and integrated across diverse clinical purposes and workflows. Using a structured assessment template, we analyzed international initiatives and industry‐led innovations to identify the clinical gaps addressed, underlying technologies, use cases, and real‐world implementation experiences. The resulting profiles highlight a broad spectrum of AI‐driven and enabled applications, including wearable sensors with haptic feedback for objective symptom monitoring; patient‐initiated teledermatology platforms that enhance access to specialist care; non‐invasive diagnostic tools employing impedance spectroscopy; autonomous triage systems for dermoscopic lesions; and sensors that combine intrinsic skin biomarkers with exposome analytics. Collectively, these technologies illustrate a shift toward generating objective, reproducible data that complement clinical assessment, facilitating earlier detection, streamlined referrals, and longitudinal, patient‐centred care. While validation studies are encouraging, regulatory and reimbursement pathways, along with limited data diversity, are current hurdles to a more large‐scale adoption. By synthesizing insights from these technological approaches, this review aims to provide dermatologists with a pragmatic overview of AI‐driven health technologies as emerging, evidence‐based, commercial initiatives that may shape the future of dermatologic care.

  • Is it ethical to develop artificial intelligence dermatology tools using data from low- and middle-income countries without ensuring access?

    by Monisha Madhumita, Subitchan Ponnarasu, Anjali Ancy, Brian William Morrison

    Artificial intelligence is transforming dermatology yet often relies on data from low- and middle-income countries without ensuring reciprocal benefits. This perspective highlights the ethical imperative to address data colonialism through equitable access, fair governance and inclusive global partnerships.

  • Top Cited Papers
    Open Access

    AI and Digital Tools in Dermatology: Addressing Access and Misinformation

    by Dominique du Crest, Monisha Madhumita, Wendemagegn Enbiale, Jose Antonio Ruiz Postigo, Josep Malvehy, Shannon Wongvibulsin, Somesh Gupta, Harald Kittler, Charbel Skayem, Anjali Mahto, et al.

    Digital dermatology, which is defined as the use of digital technologies that leverage individual- and population-level skin data to improve the diagnosis, treatment, and prevention of skin diseases, has emerged as a critical frontier for bridging persistent gaps in dermatologic care. This transformation holds particular promise for addressing long-standing inequities linked to geography, income, and skin type. According to the Global Burden of Disease 2023 study, skin and subcutaneous diseases remain among the most prevalent global health conditions, contributing substantially to disability-adjusted life years. Digital tools (including teledermatology, artificial intelligence [AI], and large language models) offer new ways to extend diagnosis, education, and patient empowerment to historically underserved populations. However, these same innovations risk amplifying disparities if they are not designed and deployed intentionally. Algorithmic bias, uneven digital access, and the absence of culturally responsive models can undermine progress. In this conceptual and narrative review, we draw on expert dialogues and illustrative literature, including multistakeholder exchanges at the Skin and Digital Summit (2023-2025 ) and related global forums, to examine how digital dermatology can promote equitable skin health. We focus on 3 interlinked priorities: expanding access through scalable digital platforms, ensuring AI fairness via comprehensive and diverse datasets, and countering dermatological misinformation. Central to the latter is a bot concept described here as a dynamic cycle that analyzes scientific literature; ranks evidence; translates complex research into clear language; and delivers trustworthy, personalized guidance to both consumers and clinicians. By embedding expert oversight and evidence prioritization, such tools can ensure that accurate, actionable information reaches users at the speed and scale of the internet. Drawing on case studies (including lessons from the World Health Organization’s AI skin health app) and insights from the Skin and Digital Summit , we highlight both the transformative potential and the ethical complexities of these digital solutions. To navigate this evolving landscape, we propose the concept of radical dermatology , which confronts the reality that big tech is reshaping skin health whether we like it or not and insists that dermatologists and stakeholders lead the transformation through bold collaboration and unwavering clinical relevance.